Ian Smith - Vertex Pharmaceuticals CFO, Executive Vice President

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

  President
Mr. Ian F. Smith, CPA, is Chief Operating Officer, Executive Vice President of Vertex Pharmaceuticals Incorporated. Mr. Smith is our Executive Vice President and Chief Operating Officer, a role he assumed in September 2017. He was our Executive Vice President, Chief Operating Officer and Chief Financial Officer from January 2017 until September 2017, Executive Vice President and Chief Financial Officer from February 2006 until January 2017, our Senior Vice President and Chief Financial Officer from November 2003 to February 2006, and our Vice President and Chief Financial Officer from October 2001 to November 2003. Prior to joining us, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst Youngs U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith has served as a member of the Boards of Directors of Acorda Therapeutics, Inc., a drug development company, since February 2007, and Infinity Pharmaceuticals, Inc., a drug development company, since May 2008. Mr. Smith served on the Board of Directors of Ophthotech Corporationrationration, a biopharmaceutical company, from August 2016 to May 2017
Age: 51  President Since 2017      
617 341-6100  www.vrtx.com
Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.

Ian Smith Latest Insider Activity

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

James MichaudPerrigo Company Plc
2016
Umang VohraDr Reddys Laboratories Ltd
2013
Joseph LaRosaRegeneron Pharmaceuticals
2019
Roman TrawickiZoetis
2015
Marc CouckePerrigo Company Plc
N/A
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Glenn DavidZoetis
2016
Jeffrey NeedhamPerrigo Company Plc
2009
Raghav ChariDr Reddys Laboratories Ltd
2013
Sandra BeatyZoetis
2012
Peter PowchikRegeneron Pharmaceuticals
2006
Michael AbermanRegeneron Pharmaceuticals
2015
George YancopoulosRegeneron Pharmaceuticals
2016
J RamachandranDr Reddys Laboratories Ltd
2016
Clinton LewisZoetis
2018
Andrew FentonZoetis
2018
Alejandro BernalZoetis
2015
Stefan WeiskopfZoetis
2013
Scott JamisonPerrigo Company Plc
2011
James DillardPerrigo Company Plc
2019
Alok SonigDr Reddys Laboratories Ltd
2015

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Also Currentnly Active

Purchased over 40 shares of
few hours ago
Traded for 83.54
Purchased a lot of shares of
few hours ago
Traded for 278.25
Purchased over 90 shares of
few hours ago
Traded for 36.8
Also please take a look at World Market Map. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.